The partners expect the proposed antibody agreement to be concluded in the first quarter of next year. Meanwhile, the current alliance for dupixent (dupilumab) is not subject to revision. For more information about the company, visit www.regeneron.com or follow @Regeneron on Twitter. About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-changing drugs for people with serious illnesses. Founded and led by physicians for 30 years, our unique ability to translate science into medicine repeatedly and consistently has led to seven FDA-approved treatments and numerous development candidates, all grown in our laboratories themselves. Our drugs and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases. Sanofi-aventis, a global pharmacy leader, discovers, develops and distributes therapeutic solutions to improve the lives of all. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and New York (NYSE: SNY). Regeneron is a biopharmaceutical company that detects, develops and markets therapeutic drugs for the treatment of serious diseases. Regeneron has therapeutic candidates in clinical studies on the potential treatment of cancer, eye diseases and inflammatory diseases and has preclinical programs for other diseases and disorders. More information about Regeneron and current press releases is available on Regeneron`s global website, where www.regeneron.com Eli Lilly has joined the ranks of major pharmaceutical companies that are establishing a position in gene therapy and paying $US 26.50 per share to take control of Prevail.
The slides and management discussion will be available on the Regeneron website: www.regeneron.com on the Investor Relations presentation page at the time of the presentation. Temperature-controlled shipping with thermal packaging compliant with GDP TARRYTOWN, N.Y.